Medicamen Biotech Ltd
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 5.73Medicamen Biotech Ltd demonstrates a mixed financial performance. The company showcases strong solvency and profitability, indicating a stable financial structure and good earnings capability. Its revenue and asset growth are also positive signs. However, the company faces challenges in efficiency, particularly in managing inventory and receivables. Additionally, there's been a decline in operating profit, EPS, and net income growth recently. While the company maintains a reasonable liquidity position, there are areas needing improvement. The healthcare industry's dynamics, including regulatory changes and market competition, could further impact Medicamen Biotech's financial trajectory. Overall, Medicamen Biotech presents a picture of a company with solid foundations but facing some operational hurdles.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio4.80
- Financial Ratio4.00
- Profitability Ratio9.60
- Efficiency Ratio2.33
- Coverage Ratio8.80
- Solvency Ratio10.00
- Liquidity Ratio6.64
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBullish
- 2 HoursBullish
- 4 HoursBullish
- 1 DayBearish
- 1 WeekBearish
- 1 MonthNeutral
Health Score : 5.73Medicamen Biotech Ltd demonstrates a mixed financial performance. The company showcases strong solvency and profitability, indicating a stable financial structure and good earnings capability. Its revenue and asset growth are also positive signs. However, the company faces challenges in efficiency, particularly in managing inventory and receivables. Additionally, there's been a decline in operating profit, EPS, and net income growth recently. While the company maintains a reasonable liquidity position, there are areas needing improvement. The healthcare industry's dynamics, including regulatory changes and market competition, could further impact Medicamen Biotech's financial trajectory. Overall, Medicamen Biotech presents a picture of a company with solid foundations but facing some operational hurdles.
Overall Valuation Score
P/E RATIO (TTM)
32.98
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
32.19
P/B RATIO
1.13
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
1.61
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
0.00
EV/EBITDA RATIO
12.76
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹228.9 as on Jun 20, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Growth Score : 4.80The company's revenue and asset growth are positive, but its operating profit, earnings per share, and net income are declining. While revenue and assets are increasing, profitability is decreasing. This is a point of concern for the company. The company needs to improve on its profitability.
Revenue Growth RateExcellent
Operating Profit Growth RatePoorEarnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RatePoor| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 1.77 | 22.61 | 26.95 | -8.94 | 21.47 |
| Operating Profit Growth Rate | 20 | 0 | 0 | -41.67 | 42.86 |
| Earnings Per Share (EPS) Growth | 22.86 | -3.85 | -26.68 | -35 | 27.19 |
| Asset Growth Rate | 16.49 | 23.45 | 5.73 | 0.68 | 25.25 |
| Net Income Growth Rate | 25 | 0 | -40 | -22.22 | 42.86 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Financial Score : 4.00The company shows mixed financial performance. While capital expenditure is well-managed, there are concerns regarding earnings per share and book value. Dividend payments are sustainable, but there's room for improvement in overall financial management. The company needs to improve on its financial management.
Adjusted Earnings Per Share (Adjusted EPS)PoorCash Earnings Per Share (Cash EPS)WeakBook Value Per SharePoorDividend Per Share (DPS)WeakCapital Expenditures (CapEx)Good| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 12.5 | 11.45 | 5.82 | 4.96 | 7.26 |
| Cash Earnings Per Share (Cash EPS) | 17.5 | 16.15 | 12.31 | 10.77 | 12.14 |
| Book Value Per Share | 121.67 | 149.23 | 159.23 | 163.85 | 197.14 |
| Dividend Per Share (DPS) | 0.98 | 1.06 | 1.03 | 1.01 | 1 |
| Capital Expenditures (CapEx) | 8.6 | 6.6 | 6.3 | 2.2 | 4.8 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
Profitability Score : 9.60The company demonstrates strong profitability. The company generates healthy profits from its sales, assets, and capital employed. This indicates that the company is effectively managing its costs and generating strong returns for its investors. The company is in a good position to generate profits.
Gross Profit MarginExcellentReturn on Capital Employed (ROCE)ExcellentReturn on Equity (ROE)ExcellentReturn on Assets (ROA)AverageOperating MarginExcellentNet MarginExcellent| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 15.65 | 12.77 | 9.5 | 4.29 | 6.57 |
| Return on Capital Employed (ROCE) | 12 | 10 | 8 | 6 | 5 |
| Return on Equity (ROE) | 10.27 | 7.73 | 4.35 | 3.29 | 3.62 |
| Return on Assets (ROA) | 10.62 | 8.6 | 8.14 | 4.71 | 5.38 |
| Operating Margin | 20.87 | 17.02 | 13.41 | 8.59 | 10.1 |
| Net Margin | 13.04 | 10.64 | 5.03 | 4.29 | 5.05 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
Efficiency Score : 2.33The company is not effectively utilizing its assets to generate revenue. Its fixed assets, inventory, receivables, and capital are not being efficiently converted into sales. This can lead to lost revenue opportunities and increased carrying costs. This is a point of concern for the company. This may affect the company's profitability.
Fixed Asset Turnover RatioPoorInventory Turnover RatioWeakReceivables Turnover RatioPoorDays Sales in Inventory RatioPoorReceivable DaysPoorCapital Turnover RatioPoor| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 1.25 | 1.52 | 1.95 | 1.87 | 2.33 |
| Inventory Turnover Ratio | 6.06 | 3.42 | 3.13 | 2.56 | 2.8 |
| Receivables Turnover Ratio | 1.98 | 2.2 | 2.98 | 2.63 | 2.62 |
| Days Sales in Inventory Ratio | 60.23 | 106.73 | 116.61 | 142.58 | 130.36 |
| Receivable Days | 184.34 | 165.91 | 122.48 | 138.78 | 139.31 |
| Capital Turnover Ratio | 0.75 | 0.72 | 0.86 | 0.75 | 0.7 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
Coverage Score : 8.80The company has a good ability to meet its interest and dividend payments. It's generating sufficient earnings to cover its interest expenses, and it has a comfortable cushion to pay dividends to its shareholders. This is a positive sign for the company. The company is doing well in terms of coverage.
Interest Coverage RatioGoodEquity Dividend Coverage RatioExcellent| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 10 | 6.67 | 3.17 | 3.5 | 4 |
| Equity Dividend Coverage Ratio | 12.5 | 11.11 | 8.33 | 5.56 | 7.14 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
Solvency Score : 10.00The company exhibits very strong long-term financial stability. The company has a very low level of debt relative to its equity and assets. This suggests that the company relies more on equity than debt to finance its operations. A high equity ratio further confirms this financial strength. The company is in a very stable position for its long term liablities.
Debt RatioExcellentDebt to Equity RatioExcellentEquity RatioExcellentDebt To Asset RatioExcellent| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.04 | 0.01 | 0.01 | 0.02 | 0.02 |
| Debt to Equity Ratio | 0.04 | 0.01 | 0.01 | 0.02 | 0.02 |
| Equity Ratio | 0.96 | 0.99 | 0.99 | 0.98 | 0.98 |
| Debt To Asset Ratio | 0.03 | 0.01 | 0.01 | 0.01 | 0.02 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
Liquidity Score : 6.64The company shows a satisfactory ability to meet its short-term obligations. A positive aspect is its ability to quickly convert assets into cash. However, its cash holdings are relatively low, and operating cash flow is negative, which could pose challenges in the short term. The healthcare industry's specific working capital requirements might influence these ratios. Further analysis is needed to determine if the current liquidity position is sufficient for operational needs.
Current RatioGoodQuick RatioExcellentCash RatioWeakOperating Cash Flow RatioPoor| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.84 | 2.26 | 2.37 | 2.64 | 3.17 |
| Quick Ratio | 1.47 | 1.71 | 1.68 | 1.86 | 2.39 |
| Cash Ratio | 0.06 | 0.26 | 0.18 | 0.05 | 0.34 |
| Operating Cash Flow Ratio | 0.06 | -0.07 | -0.08 | -0.1 | -0.36 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 2 | NGL Fine Chem Ltd | 6.98 | 39.22 | Overvalued | 73.00 | 67.39 | 48.00 |
| 3 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 4 | Kilitch Drugs (India) Ltd | 6.61 | 21.54 | Neutral | 37.00 | 9.27 | 30.00 |
| 5 | Kopran Ltd | 6.60 | 25.82 | Neutral | 62.00 | 6.30 | 26.00 |
| 6 | SMS Lifesciences India Ltd | 6.59 | 21.20 | Undervalued | 45.00 | 70.68 | 19.00 |
| 7 | Infinium Pharmachem Ltd | 6.42 | 26.90 | Neutral | 22.00 | 6.43 | 14.00 |
| 8 | Sakar Healthcare Ltd | 5.81 | 58.66 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 9 | Medicamen Biotech Ltd | 5.73 | 32.19 | Neutral | 20.00 | 6.94 | 10.00 |
| 10 | Aarey Drugs & Pharmaceuticals Ltd | 5.73 | 59.71 | Neutral | 7.00 | 1.40 | 4.00 |
| 11 | Albert David Ltd | 5.63 | -272.47 | Neutral | 5.00 | -2.62 | -1.00 |
| 12 | BPL Ltd | 5.46 | -31.11 | Neutral | -4.82 | -3.00 | -8.55 |
| 13 | Zim Laboratories Ltd | 5.41 | 41.96 | Neutral | 30.00 | 1.11 | 6.00 |
| 14 | Remus Pharmaceuticals Ltd | 5.31 | 25.48 | Neutral | 57.00 | 20.97 | 46.00 |
| 15 | Ind-Swift Laboratories Ltd | 4.95 | 39.28 | Neutral | 45.00 | 4.89 | 41.00 |
| 16 | Lyka Labs Ltd | 4.77 | -23.98 | Neutral | -4.00 | -9.05 | -10.00 |
| 17 | Wanbury Ltd | 4.65 | 28.62 | Neutral | 88.00 | 18.93 | 43.00 |
| 18 | Nectar Lifescience Ltd | 3.83 | -2.67 | Neutral | -59.00 | -2.95 | -293.00 |
Balanced ManagementMedicamen Biotech Ltd.'s management presents a mixed picture. Sales have grown over the past few years, recent results indicate a decline. Profitability metrics, including OPM and net profit, have shown volatility, with a drop in the most recent quarter. The company's ROCE and ROE are relatively low compared to its peers. Promoter holding has decreased, raising concerns about the company's future. Increased borrowings also pose concerns. These factors suggest moderate effectiveness of management.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Sales Growth (2019-24) | 27.29% | Sales have grown over the past few years. |
| CONS | Recent Sales Decline | -9.34% | Recent quarterly results indicate a decline. |
| CONS | ROCE Decline | 5% | ROCE is low compared to its peers. |
| CONS | Promoter Holding Decrease | 40.46% | Promoter holding has decreased. |
Financial Performance & GrowthAverageCapital Efficiency & ReturnsWeakFinancial Health & PrudenceAverageShareholding & Ownership StructureAverageFinancial Performance & Growth
The company's financial performance shows a mixed trend. While sales have grown over the past few years, recent quarterly results indicate a decline in both sales and profit growth. The operating profit margin (OPM) has also fluctuated, with a notable decrease in the most recent quarter. This inconsistency raises concerns about the sustainability of the company's financial performance.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Sales | 113 | 115 | 141 | 179 | 163 |
| Sales Growth (%) | -10.19% | 2.43% | 22.02% | 27.29% | -9.34% |
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| OPM (%) | 16.78% | 16.57% | 10.68% | 10.54% | 12.15% | 8.01% | 11.87% | 14.86% | -5.44% |
Capital Efficiency & Returns
The company's capital efficiency and returns are relatively low. The Return on Capital Employed (ROCE) has declined over the years, indicating that the company is not efficiently utilizing its capital. The Return on Equity (ROE) is also low, suggesting that shareholder funds are not generating high returns. These metrics raise concerns about the company's ability to generate profits from its investments.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| ROCE % | 16% | 13% | 12% | 10% | 8% | 5% |
Financial Health & Prudence
The company's financial health shows some areas of concern. Borrowings have increased over the years, leading to a higher debt burden. While the dividend payout has been consistent, the increasing debt and fluctuating profits could put pressure on future dividend payments.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Borrowings | 12 | 11 | 19 | 26 | 26 | 31 | 33 |
| Dividend Payout (%) | 10% | 5% | 10% | 8% | 9% | 12% | 18% |
Shareholding & Ownership Structure
The promoter holding has seen a slight decrease over the recent quarters, which may indicate a lack of confidence or strategic shifts within the company's leadership. Institutional holding, including FIIs and DIIs, remains relatively low, suggesting limited interest from major investors. A decrease in promoter holding and low institutional interest might impact investor sentiment.
| Metric | Sep 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Apr 2025 |
|---|---|---|---|---|---|
| Promoter (%) | 43.21% | 43.21% | 43.21% | 43.16% | 40.46% |
| FIIs (%) | 1.83% | 0.19% | 0.12% | 0.12% | 0.22% |
| DIIs (%) | 0.13% | 0.20% | 0.99% | 0.69% | 0.65% |
Balanced RiskMedicamen Biotech Ltd. exhibits moderate risk due to declining profitability, increasing debt, and negative cash flows from operating activities, raising concerns about its financial stability. The high cash conversion cycle and fluctuating operating profit margin indicate operational inefficiencies. A decrease in promoter holding and low institutional interest further contribute to the overall risk profile.
Segment performance volatilityAverageForeign exchange or interest rate exposureAverageSegment performance volatility
The company's sales have shown considerable fluctuation. Examining quarterly results reveals inconsistency, where sales growth varies significantly. The large swings in sales numbers highlight the need for strategic adjustments.
Foreign exchange or interest rate exposure
Interest expenses have increased from ₹1 Cr. in Mar 2019 to ₹3 Cr. in Mar 2025. This increase in interest payments could potentially strain profitability, especially if interest rates rise.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10227.12Bullish
- SMA 20225.79Bullish
- SMA 50227.26Bullish
- EMA 10227.84Bullish
- EMA 20227.07Bullish
- EMA 50229.82Bearish
- DEMA 10229.35Bullish
- DEMA 20227.29Bullish
- DEMA 50222.09Bullish
- TEMA 10230.34Bearish
- TEMA 20229.10Bullish
- TEMA 50224.75Bullish
- MACD0.39Bullish
- ADX18.87Weak Trend
- IndicatorValueSignal
- RSI57.02Neutral
- CCI118.34Overbought
- ROC 92.98Bullish
- ROC 142.98Bullish
- ROC 250.04Bullish
- Stoch K91.69Overbought
- Stoch D91.73Overbought
- IndicatorValueSignal
- BB Upper230.79Neutral
- BB Middle225.79Neutral
- BB Lower220.80Neutral
- ATR3.15Low Volatility
- IndicatorValueSignal
- MFI64.78Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10225.75Bullish
- SMA 20226.34Bullish
- SMA 50235.05Bearish
- EMA 10227.07Bullish
- EMA 20227.62Bullish
- EMA 50235.84Bearish
- DEMA 10227.87Bullish
- DEMA 20224.45Bullish
- DEMA 50221.86Bullish
- TEMA 10229.43Bullish
- TEMA 20227.57Bullish
- TEMA 50218.67Bullish
- MACD-1.92Bullish
- ADX20.70Weak Trend
- IndicatorValueSignal
- RSI50.79Neutral
- CCI72.74Neutral
- ROC 92.29Bullish
- ROC 14N/ABearish
- ROC 250.24Bullish
- Stoch K85.34Overbought
- Stoch D71.33Neutral
- IndicatorValueSignal
- BB Upper231.54Neutral
- BB Middle226.34Neutral
- BB Lower221.15Neutral
- ATR4.72Low Volatility
- IndicatorValueSignal
- MFI36.14Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10225.88Bullish
- SMA 20228.44Bullish
- SMA 50252.65Bearish
- EMA 10227.16Bullish
- EMA 20232.32Bearish
- EMA 50245.49Bearish
- DEMA 10224.33Bullish
- DEMA 20220.95Bullish
- DEMA 50232.93Bearish
- TEMA 10227.25Bullish
- TEMA 20220.93Bullish
- TEMA 50N/AN/A
- MACD-7.90Bullish
- ADX29.04Strong Trend
- IndicatorValueSignal
- RSI43.96Neutral
- CCI-3.16Neutral
- ROC 91.41Bullish
- ROC 140.07Bullish
- ROC 25-14.88Bearish
- Stoch K37.54Neutral
- Stoch D24.94Neutral
- IndicatorValueSignal
- BB Upper240.48Neutral
- BB Middle228.44Neutral
- BB Lower216.40Neutral
- ATR8.44Low Volatility
- IndicatorValueSignal
- MFI52.82Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10227.88Bullish
- SMA 20247.87Bearish
- SMA 50257.72Bearish
- SMA 100280.62Bearish
- SMA 200322.15Bearish
- EMA 10232.33Bearish
- EMA 20242.26Bearish
- EMA 50257.83Bearish
- EMA 100280.42Bearish
- EMA 200317.29Bearish
- DEMA 10222.10Bullish
- DEMA 20227.52Bullish
- DEMA 50235.34Bearish
- DEMA 100238.29Bearish
- DEMA 200252.52Bearish
- TEMA 10222.73Bullish
- TEMA 20220.06Bullish
- TEMA 50236.12Bearish
- TEMA 100231.52Bearish
- TEMA 200240.38Bearish
- MACD-11.68Bearish
- ADX26.34Strong Trend
- IndicatorValueSignal
- RSI39.09Neutral
- CCI-69.09Neutral
- ROC 14-15.25Bearish
- ROC 25-15.78Bearish
- Stoch K12.49Oversold
- Stoch D10.86Oversold
- IndicatorValueSignal
- BB Upper290.75Neutral
- BB Middle247.87Neutral
- BB Lower204.99Neutral
- ATR13.81Low Volatility
- IndicatorValueSignal
- MFI39.55Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 20277.77Bearish
- SMA 50332.48Bearish
- EMA 20280.69Bearish
- EMA 50330.85Bearish
- DEMA 20243.19Bearish
- DEMA 50259.70Bearish
- TEMA 20239.40Bearish
- TEMA 50248.74Bearish
- MACD-27.49Bullish
- ADX21.86Weak Trend
- IndicatorValueSignal
- RSI35.57Neutral
- CCI-138.74Oversold
- ROC 14-21.17Bearish
- ROC 25-42.05Bearish
- Stoch K33.00Neutral
- Stoch D39.76Neutral
- IndicatorValueSignal
- BB Upper354.34Neutral
- BB Middle277.77Neutral
- BB Lower201.20Neutral
- ATR31.52Low Volatility
- IndicatorValueSignal
- MFI35.50Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 6292.89Bearish
- SMA 12332.65Bearish
- SMA 24402.49Bearish
- EMA 6289.45Bearish
- EMA 12330.27Bearish
- EMA 24396.96Bearish
- DEMA 6252.49Bullish
- DEMA 12261.38Bullish
- DEMA 24276.39Bearish
- TEMA 6250.85Bullish
- TEMA 12253.07Bullish
- TEMA 24N/AN/A
- MACDN/AN/A
- ADX12.81Weak Trend
- IndicatorValueSignal
- RSI48.82Neutral
- CCI-120.54Oversold
- ROC 25-53.15Bearish
- ROC 50-57.63Bearish
- Stoch K13.22Oversold
- Stoch D19.18Oversold
- IndicatorValueSignal
- BB Upper564.13Neutral
- BB Middle389.40Neutral
- BB Lower214.66Neutral
- ATR96.29Low Volatility
- IndicatorValueSignal
- MFI28.17Neutral